64 results about "Streptokinase" patented technology

Clot disruption and dissolution are achieved using a catheter having both an agitator and the ability to deliver a thrombolytic agent. The catheter is introduced to a target region with a blood vessel and the agitator manipulated to engage and disrupt a region of clot therein. The thrombolytic agent, such as tPA, streptokinase, or urokinase, is directly released into the clot at the point where the agitator is engaging the clot. In this way, the thrombolytic activity of the agent is enhanced and the dissolution of the clot is improved.

A process for inhibiting vascular proliferation separately introduces components into the eye to generate plasmin in the eye in amounts to induce complete posterior vitreous detachment where the vitreoretinal interface is devoid of cortical vitreous remnants. The process administers a combination of lysine-plasminogen, at least one recombinant plasminogen activator selected from the group consisting of urokinase, streptokinase, tissue plasminogen activator, chondroitinase, pro-urokinase, retavase, metaloproteinase, and thermolysin and a gaseous adjuvant to form a cavity in the vitreous. The composition is introduced into the vitreous in an amount effective to induce crosslinking of the vitreous and to induce substantially complete posterior vitreous detachment from the retina without causing inflammation of the retina. The gaseous adjuvant material is introduced into the vitreous simultaneously with or after the lysine-plasminogen and recombinant plasminogen activator such as recombinant urokinase to compress the vitreous against the retina while the composition induces the complete posterior vitreous detachment.

The present invention is a method of extracting infectious pathogens from a volume of blood including the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The fibrin lysis reagent is preferably composed of plasminogen and streptokinase frozen in coincident relation until the fibrin lysis reagent is needed whereby streptokinase enzymatically reacts with plasminogen to form plasmin upon thawing. The plasminogen is suspended in an aqueous salt solution prior to freezing including NaCl and Na₃PO₄.

The present invention relates to a method and apparatus for the encapsulation of substances and drugs into cells and platelets. The present invention is also related to the incorporation of thrombus dissolving drugs, such as tissue plasminogen activator and streptokinase into platelets using the apparatus described herein. The treated platelets can then be used to treat patients suffering from a thrombus blocking a blood vessel. The present invention is also related to a preparation of red blood cells that has a stable right shift of the oxygen dissociation curve.

A method of treating prostate cancer in a living mammal includes local administration of a composition that includes a therapeutically effective concentration of collagenase. In one embodiment, a method of treating prostate cancer in a living mammal includes local administration of a composition that includes a therapeutically effective concentration of collagenase and at least one of a glycosidase, a protease, a nuclease, a lipase, an esterase, a plasminogen activator, a streptokinase, and combinations thereof. Preferably a glycosidase, such as, for example, hyaluronidase, is administered. Compositions used in methods for treating prostate cancer can also include or be administered with calcium ions, a nonionic surfactant, such as, for example, Triton® X-100, and an antibiotic, such as, for example, gentamicin. Another method of treating prostate cancer in a living mammal includes activating PSA in vivo by, for example, locally administering calcium ions.

Certain embodiments of the present invention provide functionalized nanoparticles and methods of use thereof. Certain embodiments provide nanoparticles functionalized with streptokinase. Certain embodiments of the present invention provide methods for treating a pathological fibrin associated disorder (e.g., cancer) in an animal.

The present invention relates to compositions of the polypeptide EEIIMID and one or more fibrinolytic agents selected from the group consisting of scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative. The invention further relates to methods of enhancing the fibrinolytic activity, reducing the side effects due to vasoactivity caused by the fibrinolytic agents, or prolonging the half lives of the fibrinolytic agents by adding EEIIMD.

This invention discloses a thrombolytic zyme gene, a recombination protein and its preparation method relating to a thrombus dissolving material, relating to a source strain of thrombus dissolving gene and two reorganized strains containing said gene. Study shows that the zyme is a new plasmin and its vitality is 41000IUmg computed by the fibrin panel method having the function of anti-damage and suppressing protein oxidation arisen from beam, NaNO2 and H2O2.

The present invention is based on the isolation of a gene coding for streptokinase from Streptococcus equisimilis (ATCC 9542), its cloning, and expression in E. coli. Two different strategies were carried out for the production of enzymatically-active streptokinase. In the first strategy, streptokinase was expressed as an inclusion body without its signal sequence followed by purification, solubulization, and renaturation to obtain an active preparation. The purified enzyme was formulated and lyophilized. In the second strategy, enzymatically-active streptokinase is secreted into the culture medium. The enzyme was purified, formulated and lyophilized.

The present invention relates to novel mutants of Streptokinase, its functional fragments and covalently modified forms. Methods are provided for the preparation of the bacterial plasminogen activator protein, Streptokinase its muteins, species variants and their covalently modified variants that are characterized by improved therapeutic properties, such as increased proteolytic stability, extended plasma half-lives, reduced immuno-reactivity and enhanced fibrin clot specificity. The method involves either incorporating additional cysteine residues, or substituting cysteine residues for naturally occurring amino acids into non-essential regions of the protein such that the catalytic activity of the resultant protein remains largely unaltered. These cysteine variants were further modified by covalently attaching a cysteine reactive polymer such as polyethylene glycol (PEG) or sulfhydryl-reactive moieties from a group that includes fluorophore, spin labels or other small conjugates. Disclosed herein are site-specific biologically active conjugates of Streptokinases and its covalently modified variants.

The invention provides a health food for preventing and treating cardiac and cerebral thrombotic diseases and relates to the field of health foods. The health food is prepared from 2-4 parts by weight of garlics, 2-4 parts by weight of yolks, 3-4 parts by weight of poria cocos, 1-3 parts by weight of ginseng, 3-4 parts by weight of ganoderma lucidum, 90-100 parts by weight of natto, 3-4 parts by weight of pseudo-ginseng and 2-3 parts by weight of Chinese yam. The health food has effects of softening and dredging blood vessels, reducing blood fat and blood pressure, improving a cell regeneration capability and preventing and treating arteriosclerosis, contains components such as soybean polypeptide and phosphatidylcholine bilayer with functions of reducing cholesterol, softening blood vessels and preventing and treating blood vessel hardening, contains streptokinase with functions of dissolving thrombus and fat embolus and reducing blood fat and has functions of preventing and treating hypertension, myocardial infarction and cerebral hemorrhage.

There is disclosed novel peptides, fragments or analogues thereof and polynucleotides encoding the same, obtained from streptokinase suitable for use in the amelioration of cell death and methods related thereto.

Human plasminogen activator analog peptide and its production are disclosed. It is based on protein molecule interaction critical theory and uses solvent of streptokinase and glycosylzyme as mechanism. It is carried out by taking human plasminogen as target protein by surface displaying technology of phagicin random polypeptide base, biological elutriating, screening, obtaining polypeptide sequence with mu Pg high affinity, and solid-phase synthesizing the analog peptide. Its advantages include small molecular weight, low immunity, simple process and easy control of product output, purity and activity. It can be used to prepare oral preparation and prevent thrombogenesis.

The invention discloses a tranexamic acid freeze-dried powder injection and a preparation method thereof, comprising the following components in parts by weight: 0.05-10 parts of tranexamic acid, 1-100 parts of freeze-dried powder proppant, and a proper mount of pH regulator. The invention belongs to hemostasis curative, is a freeze-dried powder injection, has stable performance to light, heat, oxygen, water and the like, and has no pollution as well as convenient operation, transportation and storage. The tranexamic acid freeze-dried powder injection is suitable for various haemorrhages caused by acute, chronic, local, systemic and primary fibrinolysis, trauma or operation haemorrhages of organs rich in plasminogen activators, such as prostate and the like and is used as an antagonist of tectotype plasminogen activators (t-PA), streptokinase and urokinase. The tranexamic acid freeze-dried powder injection is also suitable for thrombolytic haemorrhage caused by abortion and amniotic fluid embolism, is used for preventing or lightening haemorrhage of a haemophile after exelcymosis or oral cavity operation, haemorrhage caused by light diseases of nervous centralis pathological changes, and is used for treating hereditary angioneuroticedema and active hemorrhage of haemophile.

The present invention is directed to a method to prevent or reduce postoperative corneal subepithelial haze after excimer laser photorefractive keratectomy (PRK), laser in situ keratomileusis (LASIK) surgery. According to the method, a therapeutically effective amount of one or more plasminogen activators, most preferably urokinase (uPA), is administered topically to the surface of the affected eye at levels between 0.1 and 2,500 IU/ml, about eight to twelve times on the day of surgery, and four to eight times per day for about the next six to twelve days thereafter. The most preferred therapeutic amount is from about 0.1–1 IU uPA/ml, and also 1–10 IU/ml. Plasminogen activators that can be used in the inventions include urokinase, prourokinase, streptokinase and mutants thereof. The invention also covers topical ophthalmic compositions that include one or more plasminogen activators, most preferably uPA, to prevent or reduce postoperative corneal subepithelial haze.

The present invention discloses one kind of health food containing calcium reinforcing agent. The health food connects natto kinase or fermented soybean streptokinase in 100-5000 U/g and calcium reinforcing agent in 40-80 wt%. The health food of the present invention has the raised health effects of promoting calcium absorption with vitamin D3, promoting the chelating between bone and calcium with vitamin K2, lowering blood sugar, blood fat and blood pressure, preventing thrombus, etc. The present invention is suitable for all people, especially middle-aged people and old people.

The present invention relates to compositions of the polypeptide EEIIMI, anti-LRP antibodies, LRP antagonists, and/or one or more fibrinolytic agents comprising scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative. The invention further relates to methods of enhancing the fibrinolytic activity, reducing the side effects due to vasoactivity caused by the fibrinolytic agents, and/or prolonging the half lives of the fibrinolytic agents.

New thrombolytic protein molecules such as recombinant staphylokinase or streptokinase, urokinase, tissue plasminogen activator and the like, and suitable variants thereof, for targeting to brain tissue or any other tissue by either fusing to, or by synthesizing the candidate thrombolytic molecule(s) with a protein sequence comprising a strong amphipathic alpha helix containing protein transduction domain. Thrombolytic protein molecule(s) so engineered with the protein transduction domain is useful for enhanced uptake of such protein thrombolytic molecule(s) across the cell membranes and tissues including the blood brain barrier and find their use in the treatment of vascular thrombosis including cerebrovascular disorders caused by cerebral thrombosis or cerebral haemorrhage when used a as a therapeutic. The design and processes for cloning, expression, purification and protein transduction of such proteins across cell membranes.

A plasma-activated coating (PAC) process covalently binds enzymes in their bioactive state, has low thrombogenicity and can be robustly applied to medical devices, resisting delamination when deployed in vivo. Applying this process to attachment of proteins such as enzymes that inhibit thrombosis and anticoagulants such as heparin or heparin fragments, one can produce medical devices and other materials for use in vascular applications having a number of benefits including covalent attachment, not requiring intermediate linkers or chemistry; substrate independent works on polymers, metals, ceramics, 3D shapes like stents, valves, etc.; bioactivity is retained; surface may retain greater bioactivity over time in vivo; Simultaneously supports endothelialisation; can be stored for long periods, following freeze drying, and retains effectiveness when rehydrated and; surface is able to bind many fibrinolytic enzymes such as streptokinase, urokinase, tPA, plasmin).